Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Dose-escalation, Phase I Clinical Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Trial Profile

An Open-label, Dose-escalation, Phase I Clinical Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs I 022 (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Pharmaceutical Group

Most Recent Events

  • 14 Jun 2024 Status changed from active, no longer recruiting to completed.
  • 04 Jun 2024 Results assessing the safety, pharmacokinetics (PK) and preliminary efficacy of SPH4336 in patients with advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 02 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top